- Home
- PRTA vs CEVA Comparison
PRTA vs CEVA Comparison
Compare PRTA & CEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- CEVA
- Stock Information
- Founded
- PRTA 2012
- CEVA 1999
- Country
- PRTA Ireland
- CEVA United States
- Employees
- PRTA N/A
- CEVA N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- CEVA Semiconductors
- Sector
- PRTA Health Care
- CEVA Technology
- Exchange
- PRTA Nasdaq
- CEVA Nasdaq
- Market Cap
- PRTA 765.2M
- CEVA 817.6M
- IPO Year
- PRTA N/A
- CEVA 2000
- Fundamental
- Price
- PRTA $15.56
- CEVA $34.49
- Analyst Decision
- PRTA Buy
- CEVA Strong Buy
- Analyst Count
- PRTA 8
- CEVA 5
- Target Price
- PRTA $46.00
- CEVA $38.60
- AVG Volume (30 Days)
- PRTA 336.3K
- CEVA 314.8K
- Earning Date
- PRTA 02-20-2025
- CEVA 02-13-2025
- Dividend Yield
- PRTA N/A
- CEVA N/A
- EPS Growth
- PRTA N/A
- CEVA N/A
- EPS
- PRTA N/A
- CEVA N/A
- Revenue
- PRTA $135,157,000.00
- CEVA $106,939,000.00
- Revenue This Year
- PRTA $56.89
- CEVA $9.48
- Revenue Next Year
- PRTA N/A
- CEVA $10.71
- P/E Ratio
- PRTA N/A
- CEVA N/A
- Revenue Growth
- PRTA 47.92
- CEVA 9.77
- 52 Week Low
- PRTA $11.70
- CEVA $16.02
- 52 Week High
- PRTA $31.03
- CEVA $37.75
- Technical
- Relative Strength Index (RSI)
- PRTA 59.65
- CEVA 54.35
- Support Level
- PRTA $13.69
- CEVA $31.44
- Resistance Level
- PRTA $15.09
- CEVA $37.75
- Average True Range (ATR)
- PRTA 0.91
- CEVA 1.72
- MACD
- PRTA 0.13
- CEVA 0.24
- Stochastic Oscillator
- PRTA 68.56
- CEVA 52.96
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About CEVA CEVA Inc.
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.